Fujilai Co., Ltd.

Announcement on the Implementation of the 2025 Annual Equity Distribution

Legal opinion letter from Shanghai Lande (Suzhou) Law Firm regarding the 2025 Annual General Meeting of Suzhou Fushilai Pharmaceutical Co., Ltd.

Announcement of the 2025 Annual General Meeting Resolutions

Dongfang Securities Co., Ltd. on Suzhou Fushilai Pharmaceutical Co., Ltd. Summary Report on the Sponsorship of Initial Public Offering and Listing on the Growth Enterprise Market

Dongfang Securities Co., Ltd. on Suzhou Fushilai Pharmaceutical Co., Ltd. 2025 Annual Continuous Supervision Regular On-site Inspection Report

Dongfang Securities Co., Ltd. on Suzhou Fushilai Pharmaceutical Co., Ltd. 2025 Annual Continuous Supervision Training Work Report

Dongfang Securities Co., Ltd. on Suzhou Fushilai Pharmaceutical Co., Ltd. 2025 Annual Fund Storage and Usage Verification Opinion

Announcement on the Reappointment of the Company's Audit Institution for 2026

Dongfang Securities Co., Ltd. on Suzhou Fushilai Pharmaceutical Co., Ltd. 2025 Annual Continuous Supervision Tracking Report

2025 Annual Report of Independent Director (Jin Chunqing) has resigned

2025 Annual Report of Independent Director (Chen Zhong)

2025 Annual Report of Independent Director (Cao Chuanxing)

Independent Director's Work Report for 2025 (Dong Binghe)

Announcement on Holding the Performance Briefing for the Year 2025 and the First Quarter of 2026

Environmental, Social, and Governance (ESG) Report for the Year 2025

Verification Opinion from Dongfang Securities Co., Ltd. on the Internal Control Evaluation Report of Suzhou Fushilai Pharmaceutical Co., Ltd. for the Year 2025

Internal Control Audit Report for the Year 2025

Internal Control Evaluation Report for the Year 2025

Compensation Management System for Directors and Senior Management (Revised in April 2026)

Board of Directors' Work Report for the Year 2025

Announcement on Confirming the Compensation for Directors and Senior Management for the Year 2025 and the Compensation Plan for 2026

Announcement on the Proposed Purchase of Directors' and Senior Management's Liability Insurance

Notice of the Company's Annual Shareholders' Meeting for the Year 2025

Announcement of Resolutions from the 6th Meeting of the 5th Board of Directors

Announcement on the Profit Distribution Plan for the Year 2025

Quarterly Report for the First Quarter of 2026

Special Report on the Storage, Management, and Use of Raised Funds for the Year 2025

Verification Opinion from Dongfang Securities Co., Ltd. on the Securities and Derivatives Investment Situation of Suzhou Fushilai Pharmaceutical Co., Ltd. for the Year 2025

Special Report on Securities and Derivatives Investment for the Year 2025

Verification Report on the Annual Storage and Use of Raised Funds for the Year 2025

Special Audit Report on the Deduction of Operating Income for the Year 2025

Report from the Audit Committee of the Board on the Evaluation of the Accounting Firm's Performance for the Year 2025 and the Fulfillment of Supervisory Responsibilities

Special Explanation on Non-Operating Fund Occupation and Other Related Fund Transactions for the Year 2025

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for the Year 2025

Special Opinion on the Board's Self-Assessment of the Independence of Independent Directors

Annual Audit Report for the Year 2025

Annual Report for the Year 2025

Summary of the Annual Report for 2025

Pre-disclosure Announcement of Share Reduction by Some Directors and Senior Management

Legal Opinion from Shanghai Landi (Suzhou) Law Firm on Suzhou Fushilai Pharmaceutical Co., Ltd.'s First Extraordinary General Meeting of Shareholders in 2026

Resolution Announcement of the First Extraordinary General Meeting of Shareholders in 2026